Investors

FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease

Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue

Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701